Stehn JR - Search Results

1

On-target action of anti-tropomyosin drugs regulates glucose metabolism.

Kee AJ, Chagan J, Chan JY, Bryce NS, Lucas CA, Zeng J, Hook J, Treutlein H, Laybutt DR, Stehn JR, Gunning PW, Hardeman EC. Kee AJ, et al. Among authors: stehn jr. Sci Rep. 2018 Mar 15;8(1):4604. doi: 10.1038/s41598-018-22946-x. Sci Rep. 2018. PMID: 29545590 Free PMC article.

2

A small molecule inhibitor of tropomyosin dissociates actin binding from tropomyosin-directed regulation of actin dynamics.

Bonello TT, Janco M, Hook J, Byun A, Appaduray M, Dedova I, Hitchcock-DeGregori S, Hardeman EC, Stehn JR, Böcking T, Gunning PW. Bonello TT, et al. Among authors: stehn jr. Sci Rep. 2016 Jan 25;6:19816. doi: 10.1038/srep19816. Sci Rep. 2016. PMID: 26804624 Free PMC article.

3

Tumor suppressor tropomyosin Tpm2.1 regulates sensitivity to apoptosis beyond anoikis characterized by changes in the levels of intrinsic apoptosis proteins.

Desouza-Armstrong M, Gunning PW, Stehn JR. Desouza-Armstrong M, et al. Among authors: stehn jr. Cytoskeleton (Hoboken). 2017 Jun;74(6):233-248. doi: 10.1002/cm.21367. Epub 2017 Apr 26. Cytoskeleton (Hoboken). 2017. PMID: 28378936

4

Identification of Cancer-Targeted Tropomyosin Inhibitors and Their Synergy with Microtubule Drugs.

Currier MA, Stehn JR, Swain A, Chen D, Hook J, Eiffe E, Heaton A, Brown D, Nartker BA, Eaves DW, Kloss N, Treutlein H, Zeng J, Alieva IB, Dugina VB, Hardeman EC, Gunning PW, Cripe TP. Currier MA, et al. Among authors: stehn jr. Mol Cancer Ther. 2017 Aug;16(8):1555-1565. doi: 10.1158/1535-7163.MCT-16-0873. Epub 2017 May 18. Mol Cancer Ther. 2017. PMID: 28522589

5

Tropomyosin isoforms define distinct microfilament populations with different drug susceptibility.

Creed SJ, Bryce N, Naumanen P, Weinberger R, Lappalainen P, Stehn J, Gunning P. Creed SJ, et al. Eur J Cell Biol. 2008 Sep;87(8-9):709-20. doi: 10.1016/j.ejcb.2008.03.004. Epub 2008 May 9. Eur J Cell Biol. 2008. PMID: 18472182

6

Validation of an algorithm to quantify changes in actin cytoskeletal organization.

Vindin H, Bischof L, Gunning P, Stehn J. Vindin H, et al. J Biomol Screen. 2014 Mar;19(3):354-68. doi: 10.1177/1087057113503494. Epub 2013 Sep 9. J Biomol Screen. 2014. PMID: 24019255

7

Drug Targeting the Actin Cytoskeleton Potentiates the Cytotoxicity of Low Dose Vincristine by Abrogating Actin-Mediated Repair of Spindle Defects.

Wang Y, Stear JH, Swain A, Xu X, Bryce NS, Carnell M, Alieva IB, Dugina VB, Cripe TP, Stehn J, Hardeman EC, Gunning PW. Wang Y, et al. Mol Cancer Res. 2020 Jul;18(7):1074-1087. doi: 10.1158/1541-7786.MCR-19-1122. Epub 2020 Apr 8. Mol Cancer Res. 2020. PMID: 32269073

8

Specialisation of the tropomyosin composition of actin filaments provides new potential targets for chemotherapy.

Stehn JR, Schevzov G, O'Neill GM, Gunning PW. Stehn JR, et al. Curr Cancer Drug Targets. 2006 May;6(3):245-56. doi: 10.2174/156800906776842948. Curr Cancer Drug Targets. 2006. PMID: 16712460 Review.

9

New approaches to targeting the actin cytoskeleton for chemotherapy.

Bonello TT, Stehn JR, Gunning PW. Bonello TT, et al. Among authors: stehn jr. Future Med Chem. 2009 Oct;1(7):1311-31. doi: 10.4155/fmc.09.99. Future Med Chem. 2009. PMID: 21426105 Review.

10

A novel class of anticancer compounds targets the actin cytoskeleton in tumor cells.

Stehn JR, Haass NK, Bonello T, Desouza M, Kottyan G, Treutlein H, Zeng J, Nascimento PR, Sequeira VB, Butler TL, Allanson M, Fath T, Hill TA, McCluskey A, Schevzov G, Palmer SJ, Hardeman EC, Winlaw D, Reeve VE, Dixon I, Weninger W, Cripe TP, Gunning PW. Stehn JR, et al. Cancer Res. 2013 Aug 15;73(16):5169-82. doi: 10.1158/0008-5472.CAN-12-4501. Cancer Res. 2013. PMID: 23946473

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

25 results

Search Page